Does Rallies show Form 4 insider transactions for RXRX?

Yes. Rallies tracks RXRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RXRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RXRX. It does not provide personalized investment advice.

RXRX (Recursion Pharmaceuticals, Inc. Class A Common Stock) Stock Analysis - Insider Trades

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, RXRX trades at $2.96 with a market cap of $1.53B and a P/E ratio of -2.04. RXRX moved +4.04% today. Year to date, RXRX is -32.27%; over the trailing twelve months it is -34.95%. Its 52-week range spans $2.77 to $12.36. Analyst consensus is buy with an average price target of $7.38. Rallies surfaces RXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RXRX stock inside the company?

Recent RXRX insider activity includes Borgeson Blake sold 30.00K, Gibson Christopher sold 40.00K, Gibson Christopher sold 40.00K, Borgeson Blake sold 30.00K, and Gibson Christopher sold 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RXRX Key Metrics

Key financial metrics for RXRX
Metric	Value
Price	$2.96
Market Cap	$1.53B
P/E Ratio	-2.04
EPS	$-1.44
Dividend Yield	0.00%
52-Week High	$12.36
52-Week Low	$2.77
Volume	0
Avg Volume	0
Revenue (TTM)	$74.68M
Net Income	$-644.76M
Gross Margin	4.99%

Recent RXRX Insider Trades

Borgeson Blake sold 30.00K (~$105.60K) on May 5, 2026.
Gibson Christopher sold 40.00K (~$144.40K) on Apr 22, 2026.
Gibson Christopher sold 40.00K (~$124.00K) on Apr 7, 2026.
Borgeson Blake sold 30.00K (~$93.00K) on Apr 7, 2026.
Gibson Christopher sold 40.00K (~$130.00K) on Mar 23, 2026.

Latest RXRX News

REC-1245 Shows No DLTs, 43% REC-4881 Polyp Reduction; $390M Burn Guidance — May 6, 2026
Recursion Appoints Vicki Goodman as CMO Effective April 6, Taps 20 Years Oncology Leadership — Mar 25, 2026
Recursion Pharmaceuticals Drops 11.8% Monthly; Q1 EPS Seen Improving 46% — Mar 10, 2026
Recursion Pharmaceuticals Posts $74.7M Revenue and Secures $134M Sanofi Milestone — Feb 26, 2026
Recursion Q4 Loss Narrows to $0.21, Revenue Hits $35.5M, Shares Jump 11% — Feb 25, 2026

RXRX Analyst Consensus

5 analysts cover RXRX: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.38.

Common questions about RXRX

Who is trading RXRX stock inside the company?: Recent RXRX insider activity includes Borgeson Blake sold 30.00K, Gibson Christopher sold 40.00K, Gibson Christopher sold 40.00K, Borgeson Blake sold 30.00K, and Gibson Christopher sold 40.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RXRX?: Yes. Rallies tracks RXRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RXRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RXRX. It does not provide personalized investment advice.